Karla Ledoux, DO
Neurology · Lakeland, FLNPI 1760440341
Payments from drug & device makers
Across 177 payments — averaging $125.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$19K
- AbbVie$645
- EMD Serono, Inc.$522
- Novartis$287
- UCB, Inc.$278
- Lilly USA, LLC$242
- plus $1K from 32 others
What the payments were for
- Consulting fees$2501%
- Speaking & faculty fees$16,11073%
- Travel & lodging$1,2236%
- Food & beverage$4,61021%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 25 | $18,726 |
| AbbVie(2 entities) | 45 | $645 |
| EMD Serono, Inc. | 6 | $522 |
| Novartis | 10 | $287 |
| UCB, Inc. | 10 | $278 |
| Lilly USA, LLC | 17 | $242 |
| Livanova USA, Inc. | 4 | $192 |
| Pfizer | 11 | $168 |
| Amgen | 1 | $125 |
| SK Life Science, Inc. | 4 | $87 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $86 |
| Argenx US, Inc. | 2 | $60 |
| Neurocrine Biosciences, Inc. | 3 | $59 |
| Acadia Pharmaceuticals Inc | 3 | $58 |
| Neurelis, Inc. | 2 | $55 |
| MDD US Operations, LLC | 2 | $42 |
| Lundbeck LLC | 2 | $41 |
| Genentech USA, Inc. | 2 | $38 |
| Amneal Pharmaceuticals LLC | 2 | $36 |
| TG Therapeutics, Inc. | 1 | $36 |
| Aucta Pharmaceuticals, Inc. | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Avanir Pharmaceuticals, Inc. | 2 | $32 |
| GE HealthCare | 1 | $30 |
| CSL Behring | 1 | $28 |
| Biogen | 1 | $26 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| AstraZeneca | 1 | $20 |
| Grifols USA, LLC | 1 | $19 |
| Adamas Pharmaceuticals, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Microtransponder, Inc. | 1 | $16 |
| Novo Nordisk | 1 | $15 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Assertio Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,193 in reported general payments places this provider in the 75th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 12 | $70,499 |
| Nurtec OdtRimegepant Sulfate | 30 | $35,765 |
| UbrelvyUbrogepant | 24 | $29,850 |
| Emgality PenGalcanezumab-Gnlm | 17 | $18,713 |
| XcopriCenobamate | 12 | $13,930 |
| QuliptaAtogepant | 13 | $13,788 |
| Aimovig AutoinjectorErenumab-Aooe | 18 | $13,140 |
| Levetiracetam | 200 | $5,397 |
| Lacosamide | 15 | $3,158 |
| Gabapentin | 144 | $1,951 |
| Pregabalin | 87 | $1,798 |
| Pyridostigmine Bromide | 21 | $1,532 |
| Entacapone | 28 | $1,478 |
| Carbamazepine | 14 | $1,471 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 53 | $1,411 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $58 | $70,49912 claims |
| AbbVieUbrelvy, Qulipta | $645 | $43,63737 claims |
| PfizerNurtec Odt | $168 | $35,76530 claims |
| SK Life Science, Inc.Xcopri | $87 | $13,93012 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $36 | $1,53221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,434 neurology providers in Florida.
Other neurology in Lakeland
- Mark GoldsteinAtlantis$36.1M
- Derrick RobertsonTampa$27.6M
- Beth SafirsteinHallandale Beach$25.7M
- Michael PfefferMiami$24.5M
- Mark BrodyDelray Beach$20.5M
- Paayal PatelWest Palm Beach$17.3M
- Wendy BondFort Myers$14.7M
- William HoneycuttMaitland$14.1M
- Julie SchwartzbardAventura$13.6M
- Rekha GandhiWinter Park$13.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.